PIPELINE

The overarching goal of cancer immunotherapy is to drive an attack by a patient’s own immune system against tumor tissue—to destroy a tissue that the patient does not want.

Armed with the insight that successful outcomes in cancer immunotherapy rely upon mechanisms similar to those driving other forms of tissue attack by the immune system, Atreca is developing a pipeline of antibody-based oncology therapeutics, generated via its Discovery Platform, with the potential to drive anti-tumor immune responses via multiple mechanisms.

Atreca’s portfolio of antibody therapeutics has the potential to drive tumor-targeting by the immune system in multiple indications.